
zzso zzso and toxicity are three problems that limit the use of targeted toxins in solid zzso zzso 

To address zzso we used genetic engineering to develop a novel zzso zzso toxin zzso called zzso a novel zzso zzso agent created by linking human zzso growth factor zzso and zzso zzso to truncated zzso zzso zzso on the same zzso zzso zzso was reduced by mutating seven zzso zzso zzso on the zzso zzso to create a new agent, zzso zzso 

In zzso zzso zzso showed superior zzso activity compared with its zzso zzso zzso in mice was diminished by having both zzso on the same zzso allowing administration of a zzso greater dose of BLT than a mixture of zzso zzso and zzso zzso zzso retained all of its functional activity and induced about zzso fewer zzso zzso than mice given the zzso zzso zzso In zzso zzso zzso injection of the BLT showed significant ( zzso and impressive effects against two aggressive, zzso zzso zzso models when treatment was begun zzso days post zzso zzso 

These data show that zzso zzso is a promising new zzso agent that was developed to specifically address the obstacles facing clinical utility of targeted zzso 

